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Abstract In recent months, four different systems have
been reported in the literature in which CCN2 transgenes
were individually expressed in podocytes, hepatocytes,
cardiomyocytes or respiratory epithelial cells to achieve
overexpression in, respectively, the kidney, liver, heart, or
lung. These transgenic systems have provided valuable
information about the contribution of CCN2 to fibrosis in
vivo and have begun to reveal the complexities of the
underlying mechanisms involved. On the one hand, studies
of these animals have revealed that CCN2 overexpression
does not necessarily lead directly to fibrotic pathology but
may cause severe non-fibrotic tissue damage due to its
other effects on cell function (e.g. heart). On the other
hand, overexpression of CCN2 in concert with signaling
pathways associated with development (e.g. lung) or
fibrosing injuries (e.g. kidney, liver) can lead to the
initiation or exacerbation of fibrosis. The significance of
these studies is discussed in the context of the requirement
for interactions between CCN2 and co-stimulatory factors
in the microenvironment for the manifestation of CCN2-
dependent fibrosis.
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Introduction
For well over a decade, the association of connective tissue
growth factor (CCN2, also known as CTGF) with fibrotic
diseases has been the driving force behind many inves-
tigations designed to understand its biology and biochem-
istry. There are now countless studies that attest to the
importance of this molecule in fibrotic pathology. Indeed,
the initial recognition of CCN2 as a downstream mediator
of the pro-fibrogenic effects of transforming growth factor
beta (TGF-β) has resulted in elegant investigations of the
transcriptional regulation of the CCN2 gene as well as to its
recognition as a potentially superior anti-fibrotic target
(Leask et al. 2009). Extensive investigations have shown
convincingly that CCN2 expression is up-regulated in
fibrotic disorders, that it is produced temporally and
spatially in close proximity to fibrotic areas in vivo, and
that it is often localized to and a target for fibrotic (pro-
collagenic) cells (Leask et al. 2002; Rachfal and Brigstock
2005). Antagonists of CCN2 have proven effective in
blocking pro-fibrogenic CCN2 signaling pathways in vitro
and have yielded promising data with respect to preventing
or reversing fibrosis in several animal models in vivo
(Brigstock 2009).
What more, then, do we need to know? Unfortunately, as
with many other areas of CCN2 research, the devil is in the
details. The recognition of CCN2 as a matricellular protein
rather than a conventional growth factor (Rachfal and
Brigstock 2005; Leask and Abraham 2006; Chen and Lau
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molecule is involved in fibrosis. Collectively, its multi-
domain structure, association with the extracellular matrix,
utilization of multiple receptors on the cell surface
(integrins, heparan sulfate proteoglycans, low density
lipoprotein receptor-related protein, nerve growth factor
tyrosine kinase receptor), binding interactions with other
cell-regulatory molecules (TGF-β, insulin-like growth
factor, vascular endothelial growth factor), and propensity
for proteolytic cleavage into various bioactive fragments
adds many layers of complexity to its mode of action and
we have either a very rudimentary understanding or no
knowledge at all as to the importance of these or other
factors in determining the fibrotic response to CCN2.
Nonetheless, for many years there has been a dogma that
“CCN2 drives fibrosis”. Is this accurate? Data reported over
the last few months regarding some new and very
interesting CCN2 transgenic models have now begun to
shed light on this critical issue. These studies have revealed
that the consequences of CCN2 overexpression are not
necessarily predictable and that the manifestation of CCN2
fibrotic activity in vivo involves crucial interactions with
co-stimulatory signals in the microenvironment.
Transgenic systems for CCN2
Four different systems have recently been described in
which CCN2 transgenes were individually expressed in
podocytes (Yokoi et al. 2008), hepatocytes (Tong et al.
2009), cardiomyocytes (Panek et al. 2009) or respiratory
epithelial cells (Wu et al. 2009) to achieve overexpression
in, respectively, the kidney, liver, heart, or lung. Kidney-
overexpressing transgenic C57BL/6 J mice constitutively
expressed a mouse CCN2 transgene that was under the
control of a human nephrin promoter; mice were examined
up to 24 weeks of age (Yokoi et al. 2008). Liver-
overexpressing transgenic FVB/n mice were produced in
this laboratory and constitutively expressed a human CCN2
transgene that was under the control of a mouse albumin
promoter enhancer; mice were examined up to 28 weeks of
age (Tong et al. 2009). Heart-overexpressing FVB/n mice
or Sprague-Dawley rats constitutively expressed rat CCN2
under the control of a mouse myosin light chain −2
promoter; animals were examined up to 7 months of age
(Panek et al. 2009). Lung-overexpressing transgenic
C57BL/6 J mice conditionally expressed human CCN2
under the control of the Clara cell secretary protein
promoter using a deoxycycline-inducible system; transgene
expression was induced over the first 2 weeks of post-natal
life at which time the mice were examined (Wu et al. 2009).
Directed overexpression of the CCN2 transgene was
successfully documented in all of these systems. However,
the most surprising observation was that CCN2 over-
expression in the kidney, liver, or heart consistently failed
to cause any kind of fibrotic reaction whatsoever. Kidney
transgenics exhibited no glomerular abnormalities or
proteinuria while liver transgenics exhibited no hepatic
histological abnormalities or elevated liver function tests. In
contrast, the heart transgenics exhibited cardiomyocyte
hypertrophy and age-dependent heart disease which pro-
gressed from compensatory hypertrophy to ventricular
dilation and systolic heart failure—but even so these
dysfunctional hearts were not fibrotic. On the other hand,
the lung transgenic mice provided clear evidence that
CCN2 overexpression during the first 2 weeks of post-
natal life causes abnormal alveolarization and impaired
formation of the alveolar vascular network and that these
deficiencies were associated with fibrosis in and around the
alveolar septa, bronchi, bronchioles, and vessels.
How do we reconcile these findings? One possibility is
that the pro-fibrotic effects of CCN2 may be dependent on
the developmental stage of the target organ. Perhaps mere
overexpression of CCN2 in the kidney, liver or heart was
insufficient to drive fibrosis because these organs were
examined in mature animals whereas the lung transgenics
were analyzed at an early and critical time of lung
development when, possibly, the transgenic CCN2 protein
was able to interact with and somehow impair essential
growth, differentiation or maturation signaling pathways. If
this is the case, one might speculate that the pathological
sequelae of pulmonary CCN2 overexpression might be less
severe in more mature adult animals, a question that is
highly suitable to the inducible transgenic system devel-
oped for these mice. Likewise, it also would be interesting
to assess fibrosis during critical stages of organ develop-
ment in the kidney, liver and heart transgenics, although if
any such abnormality was present during pre- or early post-
natal life it appears to be resolved by adulthood.
The story does not stop there, however. Interesting
additional data were reported for the kidney and liver
transgenics that provide important clues as to the role of
CCN2 in fibrotic pathways. When the kidney transgenic
mice were challenged with streptozotocin to induce type I
diabetes, they exhibited a more pronounced glomerular
pathology than wild-type littermates in as much as they
demonstrated mesangial expansion, podocyte loss, and a
reduction in the activity of matrix-metalloprotease 2, a
matrix-degrading enzyme that is often suppressed in
fibrotic conditions. Thus the effect of the CCN2 transgene
was to exacerbate some aspects of a fibrotic phenotype in a
setting of diabetic nephropathy, although expression of
extracellular matrix components such as fibronectin or
collagen was unchanged and no fibrosis per se was
observed (Yokoi et al. 2008). A somewhat similar but more
compelling scenario was observed in our liver transgenic
2 D.R. Brigstockmice after they were subjected to liver injury by carbon
tetrachloride administration or ligation of the bile duct
(Tong et al. 2009). Both of these interventions are well-
characterized methods of inducing hepatic fibrosis yet the
transgenic mice fared worse than their wild-type littermates
as shown by the presence of more α-smooth muscle actin-
positive cells (presumptive activated hepatic stellate cells, a
principal pro-fibrogenic cell type in the liver), increased
depositionofcollagen,andelevatedmRNAexpressionofkey
fibrotic markers including α-smooth muscle actin, collagen
α1(I), and tissue inhibitor of matrix-metalloprotease-1 (the
latter of which blocks matrix breakdown and favors collagen
accumulation). This phenomenon was highly reproducible as
further exemplified by the additional data shown in Fig. 1
which illustrates that the liver transgenic mice treated
chronically with the hepatotoxin thioacetamide show a
greatly exaggerated fibrotic response in their livers as
compared to their wild-type counterparts. We have further
shown that homozygous liver transgenic mice exhibit more
severe hepatic fibrosis than heterozygous liver transgenic
mice in response to carbon tetrachloride (Tong et al. 2009).
This finding is important because it suggests that CCN2
transgene dose may also account for some of the phenotypic
variability reported between the four transgenic systems, a
question that will require clarification through further
experimental analysis.
Collectively, the observations to date support the notion
that the pro-fibrogenic properties of CCN2 are highly
contextual. Whereas normal adult tissues are seemingly
refractory to elevated CCN2 levels (at least in terms of the
fibrotic response), the pro-fibrotic properties of CCN2 are
manifested in conjunction with other changes in the
microenvironment, such as those induced by tissue damage
or during wound healing. The co-stimulatory signals that
contribute to this phenomenon may include known syner-
gistic factors such as TGF-β or fibronectin (Tong et al.
2009), changes in the level or nature of signaling through
CCN2 receptors, components of additional signaling path-
ways in injured tissues such as those associated with
inflammation, necrosis or wound healing, or modifications
to the structure or composition of the extracellular matrix
which is a reservoir of many bioactive molecules including
CCN2 itself. In addition, injured tissues contain infiltrating
immune cells and macrophages as well as specialized cells
that promote wound healing, and the presence of these cells
may be important either directly or indirectly for CCN2
fibrotic action. However, data from the heart transgenic
animals show that pathways of tissue damage or pathology
that are themselves CCN2-dependent do not necessarily
cause co-stimulatory pro-fibrogenic pathways to be trig-
gered. Further, since different strains of mice show variable
responses to common fibrotic agents (Schrier et al. 1983;
Hillebrandt et al. 2002; Bonniaud et al. 2004) as well as in
production of CCN2 itself (Cardoso et al. 2009), genetic
background likely plays an important role in influencing the
fibrotic action of CCN2.
Fig. 1 Enhanced thioacetamide-
induced hepatic fibrosis in
CCN2 transgenic livers. CCN2
FVB/n transgenic mice were
produced as described (Tong et
al. 2009). Four-week old wild-
type (a, b) or homozygous
transgenic (c, d) mice (n=4 per
group) were treated three times a
week with thioacetamide
(200 mg/kg i.p.) for four weeks.
Liver sections were stained
immunohistochemically for α-
smooth muscle actin (a, c;
brown staining) or with Sirius
Red for collagen deposition (b,
d; red staining). Staining is
shown at 10×
Connective tissue growth factor (CCN2, CTGF) and organ fibrosis 3The concept of a requirement for co-stimulants may well
prove to be the unifying feature in these animal models in
that elevated CCN2 levels are not fibrotic (e.g. kidney, liver,
heart) unless there is a background of other signaling events
produced by processes such as growth and development (e.g.
lung) or injury and wound healing (e.g. kidney, liver).
Indeed, the data obtained from the CCN2 transgenic animals
reinforce previous in vivo studies which have pointed to a
modifying rather than causative role for CCN2 in fibrosis.
For example, subcutaneous co-administration of TGF-β and
CCN2 resulted in protracted and sustained dermal fibrosis
whereas this effect was not achieved by either TGF-β or
CCN2 individually (Mori et al. 1999). Additionally, Balb/c
mice are genetically resistant to bleomycin-induced lung
fibrosis but nonetheless developed fibrosis after administra-
tion of bleomycin and a CCN2-overexpressing adenovirus
(Bonniaud et al. 2004). The behavior of CCN2 in all of
these studies is likely illustrative of its role as a
matricellular protein whereby it resides in the matrix or
is tethered to the cell surface and modifies cellular
function by ‘sensing’ changes in the environment through
its engagement of a myriad of molecular binding partners.
CCN2 has been likened to a molecular hub or adapter
(Leask and Abraham 2006), capable of integrating inputs
from multiple signaling pathways and regulating cellular
responses accordingly. Thus, ‘readouts’ for CCN2 are
highly dependent on a plethora of other molecular cues
within the microenvironment and conclusions about its
activity—including its role in fibrosis—cannot be made
without careful attention to contextual considerations. In
turn, this raises broader questions such as how to best
design meaningful mechanistic studies to probe CCN2
action (especially those that rely on in vitro approaches)
and whether components of its co-stimulatory pathways
are useful targets for fibrotic therapy in vivo.
In conclusion, CCN2 transgenic systems have begun to
provide valuable information about the fibrotic pathways
that may be triggered by CCN2 overexpression in vivo. On
the one hand, overexpression of CCN2 does not necessarily
lead directly to fibrotic pathology (e.g. kidney, liver, heart)
but can cause severe non-fibrotic tissue damage due to
other deleterious effects on cell function (e.g. heart). On the
other hand, overexpression of CCN2 in concert with
signaling pathways associated with growth and develop-
ment (e.g. lung) or fibrosing injuries (e.g. kidney, liver) can
lead to the initiation or exacerbation of fibrosis.
So, does CCN2 drive fibrosis? Sometimes yes. Some-
times no. Context is the key.
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